U.S. Representative Greg Steube (R-Fla.) led a letter on Thursday, to the Food and Drug Administration (FDA) Commissioner Robert M. Califf to request full agency compliance with their obligation under law to disclose Vaccine Adverse Event Reporting (VAERS) data for the COVID-19 vaccine.
The letter was cosigned by two other Members of the House of Representatives, Rep. Michael Cloud (R-Texas) and Rep. Tom Tiffany (R-Wis.).
“Since the COVID-19 vaccine received an Emergency Use Authorization (EUA), VAERS has received over 1.4 million reports of adverse events following the administration of the vaccine,” wrote the lawmakers. “If an adverse reaction to a vaccine is identified through VAERS, scientists at the FDA should perform further tests to determine if the vaccine presents an actual risk to public health.”
In the news :Rep. Matt Gaetz Unlikely To Face Charges, Challenger Jones Trial Scheduled In January
“Ever since the first COVID-19 vaccine received an EUA, the FDA has been noncompliant in releasing relevant data regarding the safety of the vaccine…The information contained within a VAERS report could be lifesaving. It is unacceptable that the FDA would withhold such important material from the public eye.”
VAERS is the early warning database that monitors the safety of vaccines after they are authorized for use by the FDA. Since the COVID-19 vaccine received an Emergency Use Authorization (EUA),
VAERS has received over 1.4 million reports of adverse events following the administration of the vaccine. If an adverse reaction to a vaccine is identified through VAERS, scientists at the FDA should perform further tests to determine if the vaccine presents an actual risk to public health.
The database has helped researchers establish that those who receive the COVID-19 vaccine may be at a higher risk for developing the following conditions:
- Anaphylaxis, which is a severe and potentially life-threatening allergic reaction, from the first Pfizer/BioNTech vaccinations
- Thrombosis with thrombocytopenia syndrome (TTS) after Johnson & Johnson’s Janssen Biotech COVID-19 vaccination
- Myocarditis (inflammation of heart muscle) or pericarditis (inflammation of the outer lining of the heart) after COVID-19 vaccination
- Guillain-Barré syndrome (GBS) after Johnson & Johnson’s Janssen Biotech COVID-19 vaccination
- VAERS has received over 30,700 reports of death among recipients of the COVID-19 vaccine, although no causal link between the vaccine and death has been determined
The system has been able to identify populations that may experience a more severe adverse event after receiving the vaccine based on their medical history.
In the news: Florida Gov. DeSantis Awards $1.9 Million To Expand Entrepreneurship Education And Training
In January 2022, a federal judge ordered the FDA to release at least 55,000 pages of material every month. However, the FDA is still refusing to release their analyses of VAERS data following a FOIA request for the records.
“The information contained within a VAERS report could be lifesaving. It is unacceptable that the FDA would withhold such important material from the public eye. Americans depend on the information provided in VAERS to be able to make conscious decisions about their health and well-being. It is critical that the FDA be transparent and release important sets of data to the public. We look forward to receiving your response within 30 days,” the lawmakers wrote.
Visit Tampafp.com for Politics, Sports, and National Headlines. Support journalism by clicking here to our GiveSendGo or sign up for our free newsletter by clicking here.
Android Users, Click Here To Download The Free Press App And Never Miss A Story. Follow Us On Facebook Here Or Twitter Here.
Copyright 2022 The Free Press, LLC, tampafp.com. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.